Market Access News | pharmaphorum

News

China clears ViiV, J&J injectable HIV treatment

ViiV Healthcare and Johnson & Johnson have been granted approval in China for a long-acting HIV therapy that frees patients from the need to take daily pills to keep t

News

NICE backs pump-based Parkinson’s drug from AbbVie

A therapy for Parkinson’s disease that can be delivered by a 24-hour subcutaneous infusion pump has been recommended for use by the NHS and could be an option for hundreds

News

FDA clears Servier's Tibsovo as first targeted drug for MDS

Servier has become the first company to get US approval for an IDH inhibitor as a treatment for myelodysplastic syndromes (MDS) after its Tibsovo drug was cleared by the F

News

AZ seeks FDA okay for first self-administered flu vaccine

The FDA has started a review of an extension to the labelling for AstraZeneca’s influenza vaccine FluMist Quadrivalent which would allow it to be administered by patients

News

Ipsen to refile Alagille drug after EU blocks orphan status

Ipsen has said that it plans to file a new marketing application for its treatment for itch in Alagille syndrome (ALGS), Bylvay, after failing to persuade an EMA committee

News

Pfizer sets Paxlovid price at nearly $1,400 per course

Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year

China clears ViiV, J&J injectable HIV treatment

NICE backs pump-based Parkinson’s drug from AbbVie

FDA clears Servier's Tibsovo as first targeted drug for MDS

AZ seeks FDA okay for first self-administered flu vaccine

Ipsen to refile Alagille drug after EU blocks orphan status

Pfizer sets Paxlovid price at nearly $1,400 per course

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks